 SOUTH SAN FRANCISCO, Calif., April 08, 2022 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Bio Nasdaq: NGM, a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on two late-breaking poster presentations it will give on Wednesday, April 13, 2022, at the American Association for Cancer Research AACR Annual Meeting. NGM Bio will also give an oral presentation on April 10, 2022 at the AACR meeting featuring preclinical data for the lead program in its myeloid checkpoint inhibitor portfolio, NGM707, a dual ITL2ILT4 antagonist antibody. 